- Home
- INSM vs SMMT Comparison
INSM vs SMMT Comparison
Compare INSM & SMMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- SMMT
- Stock Information
- Founded
- INSM 1988
- SMMT 2003
- Country
- INSM United States
- SMMT United States
- Employees
- INSM N/A
- SMMT N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- SMMT Biotechnology: Pharmaceutical Preparations
- Sector
- INSM Health Care
- SMMT Health Care
- Exchange
- INSM Nasdaq
- SMMT Nasdaq
- Market Cap
- INSM 12.5B
- SMMT 14.5B
- IPO Year
- INSM 2000
- SMMT N/A
- Fundamental
- Price
- INSM $72.90
- SMMT $18.59
- Analyst Decision
- INSM Strong Buy
- SMMT Strong Buy
- Analyst Count
- INSM 16
- SMMT 4
- Target Price
- INSM $83.64
- SMMT $34.75
- AVG Volume (30 Days)
- INSM 1.6M
- SMMT 2.0M
- Earning Date
- INSM 10-31-2024
- SMMT 10-30-2024
- Dividend Yield
- INSM N/A
- SMMT N/A
- EPS Growth
- INSM N/A
- SMMT N/A
- EPS
- INSM N/A
- SMMT N/A
- Revenue
- INSM $342,958,000.00
- SMMT N/A
- Revenue This Year
- INSM $18.96
- SMMT N/A
- Revenue Next Year
- INSM $41.96
- SMMT N/A
- P/E Ratio
- INSM N/A
- SMMT N/A
- Revenue Growth
- INSM 22.13
- SMMT N/A
- 52 Week Low
- INSM $21.92
- SMMT $1.89
- 52 Week High
- INSM $80.53
- SMMT $33.89
- Technical
- Relative Strength Index (RSI)
- INSM 51.18
- SMMT 44.54
- Support Level
- INSM $64.86
- SMMT $18.31
- Resistance Level
- INSM $73.95
- SMMT $20.14
- Average True Range (ATR)
- INSM 2.98
- SMMT 1.35
- MACD
- INSM 0.26
- SMMT -0.20
- Stochastic Oscillator
- INSM 72.73
- SMMT 14.71
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
About SMMT Summit Therapeutics Inc.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.